Applicant, as named in the Orange Book

Wyeth Pharms

Next listed expiry: Protonix on 7 Dec 2026. 3 products with live protection, 6 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Protonix pantoprazole sodium	pantoprazole sodium	022020	7 Dec 2026	patent
Duavee bazedoxifene acetate; estrogens, conjugated	bazedoxifene acetate; estrogens, conjugated	022247	10 Mar 2027	patent
Protonix Iv pantoprazole sodium	pantoprazole sodium	020988	12 Aug 2027	exclusivity

Recent events

25 Oct 2026Protonix Iv · Generic approved 22 Apr 2026
25 Oct 2026Inderal · Generic approved 27 Jan 2026
25 Oct 2026Premarin · First generic approved 15 Oct 2025
25 Oct 2026Premarin · Generic approved 15 Oct 2025
25 Oct 2026Premarin · First generic approved 15 Oct 2025
25 Oct 2026Premarin · Generic approved 15 Oct 2025
24 Oct 2026Duavee · Enters 12-month window basis: patent10 Mar 2027
24 Oct 2026Protonix Iv · Enters 12-month window basis: exclusivity12 Aug 2027
24 Oct 2026Protonix · Enters 12-month window basis: patent7 Dec 2026

Products without listed protection (6)

Drug	Ingredient	NDA	Earliest generic entry	Basis
Premarin estrogens, conjugated	estrogens, conjugated	020216	open now	no listed protection
Premarin estrogens, conjugated	estrogens, conjugated	010402	open now	no listed protection
Premarin · 5 strengths estrogens, conjugated	estrogens, conjugated	004782	open now	no listed protection
Premphase 14/14 estrogens, conjugated; medroxyprogesterone acetate	estrogens, conjugated; medroxyprogesterone acetate	020527	open now	no listed protection
Prempro · 4 strengths estrogens, conjugated; medroxyprogesterone acetate	estrogens, conjugated; medroxyprogesterone acetate	020527	open now	no listed protection
Protonix · 2 strengths pantoprazole sodium	pantoprazole sodium	020987	open now	no listed protection